Sage Journals: Discover world-class research

Abstract

Spanish

French

OBJECTIVE:

TO report two cases of seizures associated with the use of muromonab-CD3.

CASE SUMMARY:

TWO uremic cadaveric kidney transplant recipients had developed generalized seizures following administration of muromonab-CD3 within the first 2 days after transplantation. Seizures were treated successfully with intravenous phenytoin, and muromonab-CD3 administration was discontinued.

DISCUSSION:

The overall frequency of seizures during muromonab-CD3 administration is 6%. Uremia in patients in the early posttransplant period appears to predispose them to seizures. Seizures that happened to our two uremic patients after transplant suggest that they had been induced by muromonab-CD3 administration. The mechanism of how this could have induced seizures is unknown.

CONCLUSIONS:

Prophylactic muromonab-CD3 should be used carefully in uremic kidney transplant recipients following surgery. If therapy with muromonab-CD3 is necessary, early hemodialysis should be considered in an effort to lower the risk of seizures.

Keywords

muromonab-CD3 Seizures kidney transplantation

Get full access to this article

View all access options for this article.

References

Thistlethwaite

Gaber

Haag

Aronson

Broelsch

Stuart

OKT3 treatment of steroid-resistant renal allograft rejection. Transplantation 1987; 43: 176–84.

Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 318: 337–42.

Abramowicz

Schandene

Goldman

Crusiaux

Vereerstraeten

De Pauw

Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606–8.

Martin

Massanari

Nghiem

Smith

Corry

. Nosocomial aseptic meningitis associated with administration of OKT3. JAMA 1988; 259: 2002–5.

Adair

Woodley

O'Connell

Call

Baringer

. Aseptic meningitis following cardiac transplantation: Clinical characteristics and relationship to immunosuppressive regimen. Neurology 1991; 41: 249–52.

Coleman

Norman

. OKT3 encephalopathy. Ann Neurol 1990; 28: 837–8.

Thistlethwaite

Stuart

Mayes

Gaber

Woodle

Buchingham

Complication and monitoring of OKT3 therapy. Am J Kidney Dis 1988; 11: 112–9.

Shihab

Barry

Bennett

Meyer

Norman

. Cytokine-related encephalopathy induced by OKT3: Incidence and predisposing factors. Transplant Proc 1993; 25: 564–5.

Bechtel

Slaughter

Moore

. Seizures associated with high cerebrospinal fluid concentrations of cefazolin. Am J Hosp Pharm 1980; 37: 271–3.

10.

Moore

Bechtel

Ayers

. Effect of multidose therapy on cerebrospinal fluid penetration of cefazolin. Am J Hosp Pharm 1981; 38: 1496–9.

11.

Sollinger

. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225–32.

12.

Pichlmayr

. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321–5.

13.

Agarwal

Ostaszewski

Feld

Springate

Moxey-Mims

O'Neil

. Tumor necrosis factor and interleukin-6 in cerebrospinal fluid of a patient with recurrent adverse central nervous system events following OKT3. Transplant Proc 1993; 25: 2143–4.

Generalized Seizures Associated with the Use of Muromonab-CD3 in Two Patients after Kidney Transplantation